A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer

Published:2010-10 Issue:1 Volume:119 Page:32-37
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Friedlander Michael,Hancock Kenneth C.,Rischin Danny,Messing Mark J.,Stringer Claude A.,Matthys Gemma M.,Ma Bo,Hodge Jeffrey P.,Lager Joanne J.

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Reference42 articles.

1. Cancer statistics, 2008;Jemal;CA Cancer J Clin,2008

2. Moderate progress for ovarian cancer in the last 20years: prolongation of survival, but no improvement in the cure rate;Engel;Eur J Cancer,2002

3. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer;Neijt;J Clin Oncol,2000

4. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study;Ozols;J Clin Oncol,2003

5. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis;Bristow;J Clin Oncol,2002

Cited by 210 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of chiauranib in a combination therapy in platinum-resistant or refractory ovarian cancer: a multicenter, open-label, phase Ib and II study;Molecular Cancer;2024-08-09

2. The efficacy of tyrosine kinase inhibitors combined with chemotherapy for recurrent ovarian cancer: a systematic review and network meta-analysis;Minerva Biotechnology and Biomolecular Research;2024-05

3. Identification of a cancer associated fibroblasts-related index to predict prognosis and immune landscape in ovarian cancer;Scientific Reports;2023-12-07

4. Managing Adverse Effects of Novel Therapeutic Agents in Gynecologic Malignancies;SN Comprehensive Clinical Medicine;2023-07-06

5. Pazopanib with Topotecan weekly for patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer: results of a multicentre, open label phase I/II study (TOPAZ);Journal of Cancer Research and Clinical Oncology;2023-03-31

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3